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Abstract: Breast cancer (BC) is the second leading cause of cancer-related death in American women
and more than 90% of BC-related death is caused by metastatic BC (MBC). This review stresses
the limited success of traditional therapies as well as the use of nanomedicine for treating MBC.
Understanding the biological barriers of MBC that nanoparticle in vivo trafficking must overcome
could provide valuable new insights for translating nanomedicine from the bench side to the bedside.
A view about nanomedicine applied in BC therapy has been summarized with their present status,
which is gaining attention in the clinically-applied landscape. The progressions of drug/gene delivery
systems, especially the status of their preclinical or clinical trials, are also discussed. Here we highlight
that the treatment of metastasis, in addition to the extensively described inhibition of primary tumor
growth, is an indispensable requirement for nanomedicine. Along with more innovations in material
chemistry and more progressions in biology, nanomedicine will constantly supply more exciting new
approaches for targeted drug/gene delivery against MBC.
Keywords: breast cancer; metastasis; nanomaterials; nanomedicine
1. Introduction
Breast cancer (BC) is the second leading cause of cancer-related death in women. Over 252,710
new cases of invasive BC were diagnosed and 40,610 BC deaths were expected to occur in 2017 in
the United States alone [1]. Recently, because of rapid progression in imaging, surgery, radiation,
chemotherapy, and endocrine therapy, the mortality rate of BC patients has decreased [1]. However,
even for patients initially diagnosed with early stage disease, 20–30% will ultimately develop
metastatic disease [2]. Furthermore, more than 90% of BC-related mortality is associated with
metastasis [3], which highlights the urgent need to identify and implement more effective BC therapies.
Recent advances in genomics and cancer biology have demonstrated notable heterogeneity between
BC subtypes [4–6]. This heterogeneity can greatly contribute to metastasis, which poses a significant
challenge for designing effective BC treatments. Migration is one of the key features that a cancer
cell must obtain to successfully metastasize, and cells can gain motility through activation of the
epithelial-to-mesenchymal transition (EMT) program. EMT is typically characterized by cytoskeletal
rearrangement as well as morphological changes and is thought of as a major contributor to the
metastasis of epithelial-originated BC. In addition to enhanced motility, EMT has been shown to
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contribute to metastasis by increasing invasion and apoptosis resistance [7]. Therefore, to develop
successful treatments against metastatic breast cancer (MBC), these barriers must be overcome.
Nanomedicine is an attractive field of translational medicine that can be used against metastatic
cancer. Various forms of tumor/metastases-targeting nanomedicine have been attempted to address
this need and this field is expected to drive therapeutic research forward [8–21]. Nanomedicine offers
numerous benefits over other options, which include (i) targeted delivery to the desired sites, (ii) the
capability to load single or more therapeutic agents and, (iii) the ability to overcome solubility and
stability issues. Doxil® was the first Food and Drug Administration (FDA) approved nanomedicine
against metastatic ovarian cancer and AIDS-related Kaposi’s sarcoma in 1995, which was formulated
to improve the efficacy and reduce the toxicity of doxorubicin therapy. In 2005, Abraxane® was
approved to treat MBC and has been shown to improve tumor uptake of paclitaxel [22]. Abraxane® is
a typical albumin-bound nanoparticle with the size of 130 nm designed to avoid Cremophor® toxicities
and delivers paclitaxel through albumin-binding proteins [10–12]. Nanomedicine is also used in the
diagnosis of cancer metastasis. Cornell Dots®, currently in clinical trials, are silica spheres labeled with
radioactive iodine for PET scans, which could be used to determine metastatic sites by identifying the
location of Cornell Dots® accumulation [23]. Therefore, there is a strong potential for the expansion of
nanomedicine in to metastasis treatments to improve patient outcome.
Concurrent with the progress of nanomedicine in cancer, non-coding RNAs (ncRNAs) have also
shown great potential in treating MBC. NcRNAs are RNA molecules that do not have protein coding
capacity. Compared to conventional chemotherapeutic antineoplastic drugs, ncRNAs as therapeutics
can offer many advantages. Thousands of ncRNAs with unique sequences have been identified
within cancer cells and have been experimentally associated with cancer compared to normal tissue.
In every major cancer type, there have been reports of ncRNAs eliciting tumor suppressor or oncogenic
inducer effects [24]. The aim of ncRNA interference-based therapy is to reduce the expression of
‘uncontrollable’ genes involved in cancer, especially against undruggable targets. Over the past two
decades, while many ncRNAs have been successfully used in experimental models, their clinical
applications are limited due to lack of proper delivery systems for ncRNAs. Therefore, developing
nanomaterial-based ncRNA delivery platforms would provide additional powerful tools for the
potential treatment of various diseases including MBC.
This review will focus mainly on drug/gene including ncRNA gene delivery nanoparticles and
not on nanoparticle contrast agents for medical imaging. This review will cover the milestone advances
within this field and current clinical trials, as well as challenges and opportunities for nanomedicine in
the treatment of cancer progression and the prevention of metastasis. As a new era of personalized
cancer medicine is quickly developing, nano-delivery platforms provide more options for the modular
personalized therapies. These nano-delivery platforms in conjunction with studies of the biological
mechanisms underlying MBC metastasis will help facilitate the design of individualized strategies for
patients, and thus elongate overall survival duration.
2. Traditional Cytotoxic Chemotherapy and Targeted Therapy against MBC
Analysis of the gene expression profiles and the immunohistochemical expression of estrogen
receptor (ER), progesterone receptor (PR) and human epidermal growth factor receptor 2 (HER2),
has been used to divide breast carcinomas into five intrinsic subtypes: luminal A, luminal B,
HER2-enriched, basal and claudin-low [4]. Currently, the treatment of BC is based upon several
different factors, including BC stage and progression. The stage is mainly determined by tumor size,
number and location of lymph nodes being invaded, and the presence/absence of distant metastatic
foci [25]. Therapeutic strategies include surgical tumor resection, broad-spectrum and targeted therapy.
What makes BC difficult to treat is that each subtype has a different response to the therapeutic
strategies, thus affecting prognosis. The luminal A, luminal B, and HER2 subtypes are sensitive
to targeted hormone therapy since ER and HER2, respectively, are therapeutic targets. Although
endocrine therapy utilizing tamoxifen and raloxifene (for ER) is effective in treating luminal A and
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luminal B subtypes of BC [25,26], HER2-enriched BCs are not responsive and thus HER2-targeted
therapy using trastuzumab is developed for tamoxifen-resistant HER2-enriched BC [27]. However,
unlike luminal and HER2 subtypes, basal and claudin-low subtypes, which consist of most MBCs,
are more biologically aggressive and particularly difficult to treat. Since being characterized by the
lack of expression of ER, PR and HER2, basal and claudin-low subtypes are sometimes defined as
triple-negative BC (TNBC). Compared to non-TNBC patients, TNBC patients usually have a poor
prognosis [28]. Particularly, TNBC accounts for 15–20% of all BCs and displays higher risk of relapse
and metastasis. However due to the lack of ER, PR and HER2 expression, both endocrine and
HER2-targeted therapeutic strategies do not show tumor response in TNBC patients [26,29]. Therefore,
chemotherapy is currently the only option of systemic administration therapy for TNBC patients [30].
MBC signaling is complex. As a result, response to the treatment of MBC with a single drug is
limited and most of response rates of single-used chemotherapies on MBC patients are under 60% [25].
Moreover, the inhibition of a single pathway usually causes a high incidence of drug resistance and
tumor relapse. Although various chemotherapies can reduce tumor size [25], measurable reductions
do not necessarily correlate with an improvement in progression free or overall survival (OS) for
patients [25]. Focusing on TNBC, a study exploring the relationship between breast-cancer subtypes
and response to chemotherapy demonstrated that TNBC patients had significantly poorer rates of
progression-free survival (p = 0.04) and OS (p = 0.02), compared with the other BC subtypes [31].
This study concluded that although TNBC is responsive to chemotherapy, it is more resistant to
standard chemotherapeutics than other subtypes of breast cancer and therefore these patients have
a poorer prognosis. Over the years, combination therapy has gradually become the dominant
chemotherapy treatment method in the clinic, which could overcome multi-drug resistance and
improve patient response rate through modulation of diverse signaling pathways (synergistic
effect) [32]. Furthermore, combination therapy could improve drug efficiency at a lower administrating
dosage, and hence reduce individual drug-associated toxicity [32]. For example, the combination
of methotrexate and mitomycin C has demonstrated potent suppressing effect in MBC patients
pretreated with taxanes or anthracyclines [33]. However, due to the different pharmacokinetic profiles
of combinational drugs in vivo, the synergistic effects are largely compromised compared to in vitro
studies and conclusions are not as overwhelming as we expected.
Currently, effective strategies for treating MBC are severely lacking. Molecular-targeted therapies
are the gold standard for MBC treatment, and, to a certain extent, targeted therapies have marked a new
era of MBC treatment. The targets of these drugs mainly include serine-threonine kinases, growth
factor receptors and non-receptor signaling molecules [34]. For instance, the first clinically-applied
targeted therapy was Herceptin, a monoclonal antibody against receptor tyrosine kinase HER2 and
approved by the FDA for treating patients with HER2-positive BC in 1998 [35]. However, a single
targeted therapy is far from efficient to conquer all kinds of cancers due to inter-tumoral heterogeneity
and resistance resulting from the heterogeneity of metastatic foci. For example, it has been shown
that although chemotherapy can significantly increase 15-year survival rate of patients suffering from
early stage BC, BC recurrence and metastasis still occurred in a large proportion of these patients [36].
Hence, sufficient delivery of drug to metastatic sites remains a critical barrier to sustain the benefits of
precision medicine in MBC therapy.
3. Current Techniques Used for ncRNA Delivery in Cancer Therapy
Due to their unique mechanisms, ncRNAs have three advantages as a potential cancer therapeutic
strategy over cytotoxic chemotherapy (Figure 1A): (1) they have a high degree of safety. NcRNAs
such as microRNAs (miRNAs) elicit their roles at the post-transcriptional level of gene expression
without direct interaction with genomic DNA, so the risks of mutation and teratogenicity resulting
from miRNA gene therapy are significantly reduced. (2) they have high efficacy, and (3) they have
advantageous targeting mechanisms. MiRNAs have a large number of potential targets and high
specificity due to the principle of complementary base pairing when compared to the other small
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molecular entities. However, these advantages are not exclusive to miRNAs, as gene silencing effects
can be achieved by other ncRNAs such as small interfering RNAs (siRNAs) and double-stranded
hairpin RNAs (shRNAs).
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applied in clinical settings.
However, to become clinically relevant ncRNAs must overcome the following barriers: (1) naked
ncRNAs are quite unstable in human plasma, and (2) they are too negatively charged and large
to cross the cellular membranes. Aiming to avoid the instability issue, the currently used ncRNAs
are mainly produced by chemical synthesis and are artificially modified [37]. However, it has been
reported that these chemical modifications of ncRNAs may induce immunogenicity through toll-like
receptors [38,39]. Furthermore, in vitro/in vivo delivery of chemically modified siRNAs without of
nano-delivery vehicles remains a big challenge and has been reviewed elsewhere [40]. Delivery by
viral-vehicles is another way to efficiently introduce ncRNAs to cells, but it is highly restricted by
the safety concerns arising from intractable virions. Moreover, inherent immunogenicity is another
big issue with viral delivery vehicles, which could result in severe immune reactions and impede
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further administrations. The limited targeting capability and high cost are also problems that a viral
delivery vehicle must address. However, by taking advantage of rapidly-advancing nanotechnology,
the development of non-viral delivery vehicles containing ncRNAs could achieve their biological
effects without triggering antigenicity.
Currently, siRNAs have quickly crept into biomedical research as a new powerful tool for the
potential treatment of various diseases, and several promising clinical studies using nanotechnology
have reported success (Table 1). Therefore, the use of siRNA-based therapy is one possible therapeutic
avenue that can have success against MBC from a pharmaceutical development perspective.
Table 1. Status of various ncRNA-based nanomedicine under clinical trial.
Name Agent Delivery System Indications Company Current Status Identifier
EphA2 targeting
DOPC-encapsulated siRNA siRNA LNP Advanced cancers
MD Anderson
Cancer Center phase 1 NCT 01591356
Atu027 siRNA LNP Advancedsolid tumors
Silence
Therapeutics GmbH phase 2 NCT 00938574
PRO-040201 siRNA LNP Hypercholesterolemia Tekmira phase 1 NCT 00927459
TKM-080301 siRNA LNP Multiple cancers Tekmira phase 1 NCT 01437007
ALN-VSP02 siRNA LNP Solid tumors Alnylam phase 1 NCT 01158079
TKM-100201 siRNA LNP Ebola-virusinfection Tekmira phase 1 NCT 01518881
ALN-PCS02 siRNA LNP ElevatedLDL-Cholesterol Alnylam phase 1 NCT 01437059
ALN-TTR02 siRNA LNP Amyloidosis Alnylam phase 3 NCT 02510261
DCR-MYC siRNA LNP HepatocellularCarcinoma Dicerna phase 2 NCT 02314052
MRX34 miRNA mimic liposome various solid tumor Mirna Therapeutics phase 1 NCT 01829971
TargomiRs miRNA mimic minicells
Malignant Pleural
Mesothelioma
Non-Small Cell
Lung Cancer
Asbestos Diseases
Research Foundation phase 1 NCT 02369198
CALAA-01 siRNA
cyclodextrin
polymer-based
nanoparticle
Various
solid tumors Calando Phase 2 NCT 00689065
siG12D LODER siRNA LODER polymer Pancreatic cancer Silenseed Ltd. phase 2 NCT 01676259
DOPC: 1,2-dioleoyl-sn-glycero-3-phosphatidylcholine.
Outside of siRNAs, miRNAs represent another family of endogenous small ncRNAs which have
attracted much attention because of their ability to modulate the expression levels of target proteins
involved in almost all physiological functions. More than 2600 miRNAs have been reported in human
cells [41], and some of them have been investigated as potential MBC therapeutic agents (e.g., let-7a
targeting HER2/Aurora-B pathway [42], miR-21 targeting E-cadherin-ZEB1/2 pathway [43], miR-27a
targeting MET, EGFR, and PI3K-AKT pathway [44], miR-34a targeting AXL [45], miR-155 targeting
VHL, TP53INP1, and PI3K-AKT pathway [44,46,47], miR-181 targeting K-Ras [48], miR-200b targeting
PKCα [49], miR-221 targeting PTEN, p27kip1, p57kip2, and PUMA [50], miR-301a targeting PTEN [51]).
With current research focusing on elucidating the mechanisms and targets of siRNA and miRNA,
these provide an area of research that can deliver breakthroughs for the treatment of MBC metastasis.
However, there is still a gap in knowledge that nanotechnology can help fill. The major hurdles
including the instability in the blood and inability to pass through the cell membrane prevent siRNAs
and miRNAs from clinical use. Below we describe the two main delivery vehicles for siRNA and
miRNA, which have the general schematic as outlined in Figure 1B.
3.1. Lipid-Based Vectors for Antineoplastic Gene Delivery
Lipofectamine 2000 (lipo2000) is an extensively-used cationic lipid formulation for in vitro siRNA
transfection. Lipo2000 and another newly developed derivative, Lipofectamine RNAimax, can improve
the transfection efficiency by up to a 1000-fold [52]. Despite being effective as siRNA transfection
agents in vitro, they are toxic, which restricts its applications in therapy settings.
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Because the surface charge is negative, neutral liposomes are usually more biocompatible and
have better pharmacokinetics than cationic liposomes. 1,2-dioleoyl-sn-glycero-3-phosphatidylcholine
(DOPC) is an example of a neutral lipid and is used extensively to entrap siRNA. As shown in Table 1,
the EphA2 targeting DOPC-encapsulated siRNA liposome is currently in a phase 1 clinical trial for the
treatment in patients with advanced and/or recurrent solid tumors.
However, neutral liposomes have repulsive forces with cell membranes and are not easily
endocytosed by cells, so cationic liposomes are still preferred for transfections. Superior cationic
liposomes, such as Lipofectamine RNAimax, have also been designed to overcome the limitations
of cationic liposomes. In addition to Lipofectamine RNAimax, other superior cationic liposomes
have been designed and show promise for disease treatment. For instance, the most well-known
cationic lipid-based vector is the SNALP (stable nucleic acid lipid particle), which consists of
dioleoyl-phosphatidylethanol-amine and 1,2-dioleoyl-3-trimethylammonium-propane (DOTAP),
and is designed for in vivo delivery of therapeutic siRNAs in mammals. DOTAP is a superior
cationic lipid which has been demonstrated to form cationic liposomes with negatively charged
siRNA [53]. Extensive studies regarding the use of DOTAP-based SNALPs in disease have been
reported [16–21]. Furthermore, as shown in Table 1, Tekmira Pharmaceuticals initiated a phase 1
clinical trial of a SNALP-encapsulated siRNA targeting Plk1 (TKM080301) in adult cancer patients in
2010, and Alnylam Pharmaceuticals has initiated a phase 1 clinical trial of the first dual-targeted siRNA
drug SNALP-delivered siRNAs targeting KSP and vascular endothelial growth factor (ALN-VSP02)
for the treatment of advanced solid tumors in 2009, demonstrating that SNALPs are likely useful for
drug delivery.
3.2. Polymer-Mediated Gene Delivery Systems
Polymer-based delivery systems are usually called polymeric nanoparticles and have been used
extensively as drug nanocarriers. Cyclodextrin (CD) is one of the most reported polymers for gene
delivery, and the CD-based delivery system was first reported for the delivery of plasmid DNA in
1999. Soon thereafter CD-mediated nanoparticles advanced into clinical trials, which was the first
targeted siRNA delivery system entering clinical trials for cancer treatment [8]. In this CD-based
delivery system, both adamantane(AD)-PEG and AD-PEG-transferrin were used to improve delivery
efficacy in vivo, a process known as PEGylation. This is because AD can be stably included into
the CD core and the PEG corona can protect the nanoparticle from blood clearance by reducing the
interaction with serum proteins. However, these conjugates also decrease cellular uptake and silencing
efficacy, citing an important caveat of this system [54]. Using this system as a benchmark, Calando
Pharmaceuticals have developed CALLA-01, which targets riboneucleotide reductase to inhibit tumor
growth [55].
Although PEGylation of a nanocarrier can avoid renal clearance and phagocytosis, it should
be noted that PEGylation could also hinder the cellular interaction by a phenomenon called the
‘PEG dilemma’. Various strategies have been implemented to avoid this obstacle. We developed
a PEGylated nanoparticle (NP) using a complex coacervation of PEI/PEG-P(asp), and successfully
transfected reporter genes in vivo [13]. Despite being hidden under the PEG corona, complex
coacervation can still dominate the surface charge to be positive to facilitate the interaction with
cells. Once endocytosed, PEI in the complex coacervation could be triggered to release the cargo via
the sponge effect.
Although steps have been taken to fill in the gaps of knowledge, more research is needed to
translate therapeutic non-coding RNAs into clinical reality. For example, several clinically tested
siRNA therapeutics are administrated intravenously by synthetic carriers, and none of them have been
reported to be routinely used in the clinic. Many of the unsuccessful nanomedicine-based clinical trials
cited poor efficacy, inability to achieve primary objectives, or have safety problems. Therefore, there is
an urgent need to develop more concrete delivery systems.
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4. The Clinically Applied Drug-Based Nanomedicine against Cancer and Its Confronted Challenges
The inefficiency of traditional therapies provides a unique opportunity for nanomedicine
(Abraxane®) to intervene for treatment of MBC. Nanomedicine is a cutting-edge interdisciplinary field
that has developed rapidly and widely over the past 20 years. Originating from biology, organic and
inorganic chemistry, nanocarriers have helped medicine to treat various cancers through multiple
biological mechanisms and targets (Table 2). Lipid-based and polymeric materials constitute the
majority of the nanocarriers because of their unique properties that enable the anchorage of targeting
moieties, degrade under physiological conditions, and carry a large amount of drug molecules.
Table 2. Cancer-treating nanomedicines already approved or being applied in the clinical trials.
Brand Delivery System Indications Company Current Status
NanoTherm® Iron oxide nanoparticle
Local treatment of
glioblastomas MagForce AG Approved in Germany
Aurimmune®
Colloidal gold-bound
recombinant human tumor
necrosis factor
Pancreatic cancer CytImmune Sciences Phase 2 clinical trial
Doxil®(US)
[Caelyx®(Europe)]
PEGylated
liposome doxorubicin Ovarian/BC
Orthobiotech,
Schering-Plough FDA approved
Abraxane®
Albumin-bound
Paclitaxel nanoparticles Various cancer therapy Abraxis Bioscience FDA approved
Nab paclitaxel in combination
with gemcitabine
Metastatic pancreatic
cancer Celgene FDA approved
Myocet®
Non-PEGylated
liposome of Doxorubicin BC therapy
Elan
Pharmaceuticals/Sopherion
Therapeutics
Approved in Europe
and Canada
DaunoXome®
Liposome-encapsulated
Daunorubicin
Advanced HIV-associated
Kaposi sarcoma Gilead Science FDA approved
DepoCyt® Liposomal Cytarabine Lymphomatous meningitis Pacira Pharms Inc. FDA approved
Oncaspar® PEGylated L-asparaginase
Acute Lymphocytic
Leukemia Sigma Tau FDA approved
Onco-TCS® Liposomal Vincristine Non-Hodgkin Lymphoma Inex Phase 1/2 clinical trial
LEP-ETU® Liposomal Paclitaxel
Ovarian/breast/lung
cancers Neopharma Phase 1/2 clinical trial
Aroplatin® Liposomal Cisplatin analog Colorectal cancer Antigenics, Inc. Phase 1/2 clinical trial
OSI-211 Liposomal Lurtotecan Lung cancer/recurrentovarian cancer OSI Phase 2 clinical trial
SPI-77 PEGylated liposomal Cisplatin Head and Neckcancer/Lung cancer Alza Phase 3 clinical trial
EndoTAG-1 Paclitaxel embedded inliposomal membranes BC/Pancreatic cancer
Medigene/SynCore
Biotechnology Phase 2 clinical trial
Marqibo® Vincristine
Philadelphia
chromosome-negative
lymphoblastic leukemia
Talon Therapeutics FDA approved
ThemoDox® Doxorubicin Hepatocellular carcinoma Celsion Corporation Phase 3 clinical trial
Atragen®
Liposomal all
trans-retinoic acid
Acute
promyelocytic leukemia Aronex Pharmaceuticals Phase 2 clinical trial
Lipoplatin® Liposomal Cisplatin
Pancreatic/Head and
Neck/BC Regulon Phase 3 clinical trial
Aurimmune®
(CYT-6091)
TNF-α bound to colloidal gold
nanoparticles Head and Neck cancer Cytimmune Sciences Phase 2 clinical trial
Auroshell® Gold nanoshell
Thermally destroy the
tumor tissue Nanospectra Bioscience Phase 1 clinical trial
Genexol-PM®
Polymeric micelle loaded
with paclitaxel BC/small cell lung cancer Samyang
Approved in
Europe and Korea
Paclical® Paclitaxel micelles Ovarian cancer
Oasmia Pharmaceutical
AB Phase 3 clinical trial
Narekt-102 PEGylated liposome loadedwith Irinotecan Breast/Colorectal cancer Nektar Therapeutics Phase 3 clinical trial
NKTR-105 PEG-Docetaxel conjugate Solid tumors Nektar Therapeutics Phase 1 clinical trial
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Advances in nanotechnology greatly contribute to our ability to treat MBC. One such example of
nanomedicine applied in BC treatment is Abraxane®. Paclitaxel has poor water solubility and hence
usually formulates with a large amount of polyoxyethylated castor oil (Cremophor®). This formulation
is favorable for drug delivery because of its favorable safety profile and greater therapeutic index
compared with standard paclitaxel (Cremophor®-based) in patients. However, Cremophor® is not
an inert excipient and has been shown to demonstrate unwanted reactions. Therefore, Abraxane®
was developed to avoid these complications while improving drug delivery. In a phase 3 clinical
trial against MBC, Abraxane® was administered at 260 mg/m2 every 3 weeks (q3w) while standard
paclitaxel was administered at 175 mg/m2 q3w [10]. This study demonstrated that Abraxane® had
a much lower incidence of grade 4 neutropenia, a significantly superior overall response rate (RR)
and a significantly longer time to progression (TTP). However, it was also found that Abraxane® did
not show any significant improvement on patient OS, suggesting this nanomedicine has a limited
success in this trial. One possibility for the inability of Abraxane® to improve OS is due to the
inadequate targeting capability of the particle. Additionally, there have been 7 albumin-binding
proteins discovered, a large portion of which are located at the normal cells apart from tumor cells [56],
therefore the drug could have bound to any of these proteins instead of its intended target. However,
more research will need to be done to identify the potential uses for Abraxane®.
In addition to paclitaxel in Cremophor®, Abraxane® has also been compared to docetaxel for the
treatment of MBC in clinical trials. In this study, Abraxane® administered by three distinct dosing
regimens (300 mg/m2 intravenous q3w, 150 and 100 mg/m2 intravenous the first 3 of 4 weeks (qw 3/4))
was compared to docetaxel (100 mg/m2 intravenous q3w). RRs were similar between Abraxane® and
docetaxel given q3w (33% vs. 36%) [11,12]. However, the 150 mg/m2 qw 3/4 dose of Abraxane® was
found to be a significantly more effective regimen than docetaxel [12], and median OS of 150 mg/m2
qw3/4 was 33.8 months compared with 26.6 months for docetaxel [12].
Although the efficacy of nanotherapeutics is improving, it is still a major challenge for engineers
to consider the limited therapeutic efficiency against MBC metastasis. Increasing evidence suggests
that the regulation of metastasis differs greatly from primary tumor inhibition, and therefore casts
doubt on the clinical validity of using traditional nanomedicine. For example, the large particle sizes
can hinder the delivery of Abraxane® and Doxil® deep into the tumor parenchyma, which resulted
in only a modest survival benefit to patients [10,57–59]. Furthermore, single use nanomedicines
were also found to be inefficient in treating MBC metastasis [14,60]. One of the major challenges
that face nanomedicine remains the ability to target the metastatic lesions within a large population
of normal cells, which are substantially distinct from the primary tumor. For example, traditional
nanotherapeutics methods that are effective for treating primary tumors via Enhanced Permeation
and Retention (EPR) effect may be inadequate while dealing with small clusters of disseminated
malignant cells. Another major challenge is the limited in vivo stability of nanoparticles. However,
many nanoparticles reportedly claim their excellent stability via demonstrating the extended in vitro
release profile, and most of them will dissociate when suffering from shearing forces in the circulation
system and the premature-released payloads must arrive at the desired sites in a low efficiency
without any passive or active targeting effects. It has been reviewed elsewhere that Abraxane® did not
show significantly improved pharmacokinetics and biodistribution due to the rapid dissociation upon
intravenous injection and thus contribute little to OS [61]. Prior to talking about the targeting effect from
nanomedicine, more advances are still needed to provide more concrete groundwork for developing
nanoparticles with better in vivo reliabilities. Hence, a better understanding of the fundamental
processes involved, which include nanoparticle circulation, biodistribution, tumor/metastases
targeting, and tumor/metastases penetration, is desperately needed to overcome the major hurdles in
nanoparticle-based therapy.
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5. Biological Challenges Associated with Treating MBC
To achieve the therapeutic goal, it is important to understand the complexity and interplay
between the biology of MBC metastasis and the fabricated nano-system.
5.1. Challenge 1—Limited Access to the Dormant Cells or Micrometastases
Compared to the eradication of primary tumors, identification and delivery of therapeutic agents
to metastatic lesions is a much bigger challenge. Once the cancer cells are disseminated into a secondary
organ, there are three distinct kinds of niches that coexist within the metastatic lesion: single dormant
cells, dormant micrometastases, and actively growing and vascularized metastases, which may be
detected by their effects on vital organ function or by various imaging instruments [62]. To date,
few studies have investigated the effects of drugs on dormant cancer cells. In models of BC metastases
to the liver, cytotoxic chemotherapy effectively inhibited the development of metastases, but had little
effect on the elimination of dormant cancer cells disseminated to liver [63]. Furthermore, another
study demonstrated that chemotherapy treatment given at the early stage of metastasis had no effect
on late-developing BC metastases, presumably due to a dormant state of the cancer cells at the
time of treatment [63]. Therefore, dormant cancer cells remain an elusive target for therapy using
small-molecular drugs and provide a greater challenge for nanomedicine which uses a much larger
size to deliver therapeutic agents. When used to target micrometastases and poorly-vascularized
metastases, nanotherapeutics also encounter the same problem. The primary tumor vasculature
can have fenestrae up to 600 nm and tumor-associated lymphatic drainage is often poor, therefore,
some solid tumors will exhibit an EPR effect for nano-vehicles [64]. However, the EPR effect is only
present in tumors of more than ~100 mm3 in volume, and fails in the unvascularized metastases [65].
This greatly hinders the application of nanotherapeutics in the treatment of MBC metastasis. Similarly,
the strategy of targeted delivery has been well established for primary tumors, but it only has a few
applications in the treatment of metastatic foci (Figure 2). The targeting method may be adapted to
metastases by addressing unique site tags on the populations of cells that form metastatic foci or by
exploiting the metastatic phenotype, but identifying these unique tags is still in its infancy. Generally,
the smaller size, dispersion in the body, and the presence of less vasculature than primary tumors are
unique physiological barriers of metastases, which make metastases less accessible to molecular and
nanoparticle agents [66].Nanomaterials 2018, 8, x FOR PEER REVIEW  10 of 18 
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5.2. Challenge 2—The Anti-Apoptosis Characteristic of Cancer Stem Cells (CSCs)
In general, undifferentiated CSCs seem to coexist with the fully differentiated end stage cells and
partially differentiated transit amplifying cells simultaneously in breast carcinoma [67]. One feature
that helps to define a CSC is its unique ability to resist apoptosis [3]. Metastasis is a truly inefficient
process-despite of large number of cells migrating away from primary tumor, only a few successfully
colonize a secondary organ. One proposed reason is provided by the CSC model, which hypothesizes
that colonization can only be achieved by CSCs, which are rare within BC primary tumors [68,69].
As few as 100 to 200 breast CSCs have been shown to develop tumors when being inoculated into the
mammary fat pad of immunocompromised mice [70]. Furthermore, CSCs are one of the major causes
of treatment resistance in MBC patients. This resistance presumably stems from two sources: (1) CSCs
often retreat from the activated G1/S phase into G0 phase; and (2) the close association between CSCs
and the mesenchymal cancer cells. Mesenchymal cells have been shown to be the product of EMT and
typically exhibit intrinsic drug resistance [71]. In support of this, various studies have identified that
the drug-resistant cancer cell subtype often exhibit a more mesenchymal-like phenotype [72].
6. Designing Nanomedicine Strategies to Overcome the Limitations in MBC Metastasis
Metastasis is a particularly complex process, and metastatic dissemination constitutes the
following steps including: invasion of surrounding tissues, entry into the microvasculature of the
lymphatic and blood systems, transportation by the circulatory system, arrest and survival in the
microenvironment of secondary organs, and finally, colonization [73]. From a treatment landscape,
understanding the underlying mechanisms of the early steps is important for the treatment of
early-stage MBC patients, whereas understanding the mechanisms of successful colonization is very
important for the effective therapies for patients with already-established metastasis [3]. Accordingly,
the complex metastatic cascade can be simplified into two major steps: (1) physical translocation of
the cancer cells away from the primary tumor to secondary organs and (2) colonization of distant
organs. The distinct capabilities of nanoparticles in targeting, detection and trafficking in vivo [74],
are expected to enable novel approaches to effectively target both of these steps. However, the genetic
and biochemical determinants of CSC colonization at the secondary site are unclear, which renders
more difficulties to the rational design of nanomedicine. As the biological mechanisms of tumor cell
dissemination are disclosed, feasible nanotherapeutics approaches to treat MBC may be designed
accordingly (Figure 3).Nanomaterials 2018, 8, x FOR PEER REVIEW  11 of 18 
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6.1. Preventing the Physical Translocation Away from Primary Tumor to Secondary Organs
6.1.1. Targeting Epithelial-to-Mesenchymal Transition (EMT) of Primary Tumor
Targeting the primary tumor with anti-migratory ncRNAs to keep cells in place is currently very
effective in preclinical studies. During the EMT process, normally polar, epithelial breast cells switch
to a more motile and invasive mesenchymal-like phenotype. Certain families of miRNAs have been
found to potently regulate EMT. For instance, the miR-200 family, known for directly targeting the
E-cadherin suppressors zinc finger E-box binding homeobox 1 and homeobox 2 (ZEB1 and ZEB2),
was found as a promising family against cancer metastasis [75,76]. More specifically, the miR-200
family member, miR-200b, prevents TNBC cell migration and metastasis by suppressing Protein Kinase
Cα (PKCα), which is a member of PKC family of serine/threonine kinase constituted by 10 isozymes,
crucial in regulating cell migration and TNBC metastasis [49].
Furthermore, other miRNAs have also been shown to have potential therapeutic effects against
EMT clinically. miR-34a was found to be significantly downregulated in TNBC cell lines. One of
the direct targets of miR-34a is AXL, which is a member of the TAM (TYRO3-AXL-MER) receptor
tyrosine kinase family and plays a diverse role in survival, proliferation, migration, invasion and
angiogenesis [45]. High AXL expression level correlates with poorer prognosis of MBC patients [77],
and therefore has emerged as a promising target for cancer therapy. Various AXL inhibitors have
been developed, but only one has been found to be efficacious against MBC metastasis in a preclinical
study [78]. A nanoparticle-mediated miR-34a mimic (MRX34) was reportedly developed, and has
become the first microRNA-based therapy to reach phase 1 clinical trials in 2013 [15]. However,
this study was terminated by FDA in 2016 because of immune-related severe adverse events, likely
caused by the applied delivery vehicles. This further emphasizes the importance of studying and
elucidating the mechanisms of an effective systemic delivery system, including viral and non-viral
vehicles. Currently, the non-viral vehicles mainly consist of nanoparticle-based delivery systems.
Compared to systems delivering other kinds of gene therapeutics, the delivery of miRNAs is especially
challenging because of the natural characteristics of miRNAs. As an emerging delivery mechanism,
nanotechnology is a valuable tool for clinical application of miRNA-based therapies.
Since EMT is closely correlated with chemo-resistance [79], the design of a drug/gene codelivery
system to attenuate CSCs and EMT is a potential avenue to avoid drug resistance and relapse of MBC.
Hammond and colleagues, have developed a multi-layered nanoparticle for systemic codelivery of
siRNA and doxorubicin for MBC treatment [80]. The advantage of this codelivery system is that the
attenuation of the corresponding gene(s) could create a transient time window in which the resistant
MBC cells become vulnerable to the antineoplastic drug, thereby overcoming multidrug resistance
resulting from MBC. Furthermore, development of intelligent gelatinase-sensitive nanoparticles
co-delivering docetaxel and miR-200c was also able to inhibit EMT and showed promise for cancer
therapy [81]. Both examples provided very good reference for MBC treatment.
6.1.2. Blocking the Spread through the Lymphatic System
MBC cells mainly metastasize through the circulation system, and they can spread through
lymphatic or hematogenous routes. The first metastatic sites are often the lymph nodes close to tumor,
and therefore the presence of lymph node metastasis correlates with more metastasis and poorer
prognosis [82]. Targeting the lymph nodes via nanoparticles could be one method to stop the spread of
MBC cells. Since cancer cells elicit an immune response, nanotechnology can take advantage of this
process and nanoparticles can be bound to the leukocytes and then transferred to lymph nodes together
with therapeutic agents [83]. One successful strategy is using carbohydrate (e.g., dextran)-coated
iron-oxide nanoparticles which have an improved accumulation in lymph nodes, due to the enhanced
uptake by leukocytes in circulation [84–86]. Furthermore, another study demonstrated a therapeutic
effect of an iron-loaded nanoparticle-ferumoxytol, which is now approved by the FDA for treating
iron deficiency, that showed promise against early BCs and lung cancer metastases in the liver and
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lungs [87]. Increased mRNA levels associated with pro-inflammatory Th1-type responses was found
on macrophages exposed to ferumoxytol, and cancer cells co-incubated with ferumoxytol showed
elevated caspase-3 activity. This result suggests that iron-loaded nanoparticles could protect the distant
organs from metastatic seeds by modulating macrophage responsiveness.
Another strategy is using the ultra-small nanoparticles with higher permeability to the lymphatic
systems. Although the primary tumor and sentinel lymph nodes could be removed by the surgery, it is
hard to treat the tumor cells still residing in the lymphatic vessels [88,89]. The prevention of lymphatic
metastasis is critical for clinical MBC treatment, and the role of the lymphatic system has been the under
the direct attention for the development of suitable drug-delivery strategies. Ultra-small nanodrugs
(10~30 nm in diameter) have been successfully applied against tumor metastasis, whose mechanisms
can be directly related to their lymphatic accumulation [90–93].
6.2. Interfering with the Colonization of Distant Organ Sites
Metastatic suppressor genes provide gene targets for the regulation of the colonization of
distant organ sites within the metastatic cascade. Promoting metastatic dormancy through metastatic
suppressor genes has proven to be an effective way to prevent colonization of the already disseminated
MBC cells. The first and most reported metastatic suppressor gene is the human nonmetastatic
gene 23 (Nm23-H1), which could abrogate metastasis development without growth inhibition of the
primary tumor [94]. Mechanistically, lysophosphatidic acid receptor 1 gene (LPA1) has an inverse
expression and functional interaction with Nm23-H1, and the inhibitor of LPA1 (Debio-0719) was found
to effectively function as a metastatic suppressor, which could induce metastatic dormancy of MBC
cells [95]. As a highly hydrophobic small molecule, Debio-0719 seems to have minimal chances being
applied in real clinical activities, but it would be expected to take advantage of nanotechnology to
solve the poor solubility in physiological aqueous environment. However, Debio-0719 presents a new
drug development paradigm to induce MBC cell dormancy in metastatic sites.
Anti-apoptosis is an important mechanism of metastatic cancer cells [96], and therefore a critical
intervention point for the treatment of metastasis. Recent studies have also demonstrated that
the apoptotic resistance of CSCs is essential for metastasis, and recent studies have proved that
the induction of apoptosis in these cells could prevent metastasis. Several lines of evidence
support this hypothesis. First, it has been shown that the metastatic potential of both human and
murine cells is positively correlated with the anti-apoptotic propensity of the cells when injected
into immunocompromised mice [97]. Second, experimentally-manipulating key anti-apoptotic or
pro-apoptotic factors could influence overall metastatic efficiency, as BC cells overexpressing exogenous
BCL2 induced an increased number of lung metastases in vivo [98]. Third, the inactivation of
pro-apoptotic genes promotes metastasis. Loss of p53 function has been associated with MBC metastasis
clinically [99]. Similarly, HCCR-2, human cervical cancer oncogene encoding a negative modulator of
p53, could promote transgenic mice to develop BC and metastasis [100].
Moreover, data from human metastatic tumors indicate that the gain-of-function of anti-apoptotic
genes (e.g., survivin, Nuclear Factor κB (NFκB) or BCL2) or the loss of function of pro-apoptotic
genes (e.g., BAX, p53 and death-associated protein kinase (DAPK)) closely correlate with the tumor
progression [101,102]. Particularly, studies have focused on survivin because it was found that
expression is low in normal tissues [103], and overexpressed in most malignant tumors [104]. It has
also been reported that TAT-g-CS/siRNA nanoparticles targeting survivin strongly inhibited the
proliferation of TNBC cells via inducing cell apoptosis both in vitro and in vivo, and thus reduced
TNBC metastasis in vivo [9]. Conversely, DAPK is a positive apoptosis mediator and could be
used for the suppression of in vivo metastasis [101]. Hence, we stress the induction of apoptosis
in CSCs has a crucial role during the metastasis treatment, which could be taken advantage of by
nanomedicine design.
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7. Summary and Future Perspectives
This review summarizes the latest progression of NP-mediated drug/gene delivery systems
against cancer within the past few decades, focusing on the advancement of using nanomedicine
for MBC treatment. However, despite the great improvements of Abraxane® in MBC treatment,
substantial efforts are still needed to overcome the physiological barriers hindering nanoparticle
delivery to metastases. Furthermore, we discussed nanomedicine designing strategies based on the
biological development of MBC. To translate these applications into real clinical use, scientists must
further optimize the nanomaterials to adapt to the challenges of a sophisticated in vivo environment.
The summarized gene delivery systems in this review exhibit great potential against MBC, but still
need extra effort to adapt to use in vivo. The use of targeting ligands specific for overexpressed
receptors at metastatic sites, is still a driving force for the development of nanomedicines. Continued
improvements of nanomedicines will lead to advancements of clinical testing for MBC patients apart
from Abraxane®.
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